NYSE - Delayed Quote USD

Danaher Corporation (DHR)

Compare
235.84 +0.79 (+0.34%)
At close: November 22 at 4:00 PM EST
236.50 +0.66 (+0.28%)
After hours: 7:58 PM EST
Loading Chart for DHR
DELL
  • Previous Close 235.05
  • Open 234.49
  • Bid 235.86 x 800
  • Ask 235.95 x 800
  • Day's Range 234.73 - 236.84
  • 52 Week Range 215.68 - 281.70
  • Volume 2,329,993
  • Avg. Volume 2,607,996
  • Market Cap (intraday) 170.341B
  • Beta (5Y Monthly) 0.88
  • PE Ratio (TTM) 44.41
  • EPS (TTM) 5.31
  • Earnings Date Jan 28, 2025 - Feb 3, 2025
  • Forward Dividend & Yield 1.08 (0.46%)
  • Ex-Dividend Date Sep 27, 2024
  • 1y Target Est 290.13

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

www.danaher.com

61,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DHR

View More

Performance Overview: DHR

Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DHR
2.27%
S&P 500
25.15%

1-Year Return

DHR
8.71%
S&P 500
31.54%

3-Year Return

DHR
14.28%
S&P 500
27.06%

5-Year Return

DHR
89.51%
S&P 500
92.34%

Compare To: DHR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DHR

View More

Valuation Measures

Annual
As of 11/22/2024
  • Market Cap

    170.34B

  • Enterprise Value

    185.24B

  • Trailing P/E

    44.50

  • Forward P/E

    27.70

  • PEG Ratio (5yr expected)

    3.15

  • Price/Sales (ttm)

    7.37

  • Price/Book (mrq)

    3.32

  • Enterprise Value/Revenue

    7.80

  • Enterprise Value/EBITDA

    25.80

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.39%

  • Return on Assets (ttm)

    3.86%

  • Return on Equity (ttm)

    7.59%

  • Revenue (ttm)

    23.74B

  • Net Income Avi to Common (ttm)

    3.93B

  • Diluted EPS (ttm)

    5.31

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.63B

  • Total Debt/Equity (mrq)

    36.69%

  • Levered Free Cash Flow (ttm)

    5.17B

Research Analysis: DHR

View More

Company Insights: DHR

Research Reports: DHR

View More

People Also Watch